Which laboratory study is crucial for monitoring a client on clozapine (Clozaril)?

Monitoring the white blood cell count is essential for patients on clozapine (Clozaril) due to the risk of agranulocytosis, a potentially life-threatening side effect characterized by a dangerously low white blood cell count. Clozapine has been associated with a significant risk of this condition, particularly in the initial months of therapy, which can increase the risk of infections.

Regular blood tests to monitor the white blood cell count and specifically the absolute neutrophil count (ANC) are required to ensure the client remains within safe limits. If the ANC falls below a certain threshold, clozapine therapy may need to be adjusted or discontinued, risk of infection must be managed, and alternative treatments may need to be explored. Proper monitoring helps in early detection and management of this side effect, promoting the safe use of clozapine as an effective treatment for resistant schizophrenia.

While other laboratory tests can provide useful information for overall health or medication side effects, they do not specifically address the critical safety concern associated with clozapine therapy.